Why We Invested In Teiko — Mapping Immune Profiles To Improve Clinical Outcomes

[table id=7 /] Excited to announce our seed investment in Teiko.bio, which calculates an immune fingerprint for each person. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in mature seed, typically when there is a pipeline of customers, but we occasionally take earlier or later bets when we see immense promise. Teiko falls on that first exception, having been just founded at the end of 2020, but impressing us with (1) addressing a strong need, (2) building an execution-focused team, and (3) creating a differentiated product. 1) The Need Helping design more immune-specific clinical trials and therapies…...